Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 413,500 shares, a growth of 863.9% from the December 15th total of 42,900 shares. Based on an average daily volume of 868,300 shares, the days-to-cover ratio is currently 0.5 days. Approximately 4.6% of the shares of the company are short sold.
Several institutional investors have recently made changes to their positions in BLPH. JPMorgan Chase & Co. lifted its holdings in shares of Bellerophon Therapeutics by 242.5% in the second quarter. JPMorgan Chase & Co. now owns 6,507 shares of the biotechnology company’s stock worth $31,000 after buying an additional 4,607 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Bellerophon Therapeutics in the second quarter worth about $59,000. Ergoteles LLC purchased a new stake in shares of Bellerophon Therapeutics in the second quarter worth about $67,000. Virtu Financial LLC purchased a new stake in shares of Bellerophon Therapeutics in the second quarter worth about $80,000. Finally, Telemetry Investments L.L.C. lifted its holdings in shares of Bellerophon Therapeutics by 48.9% in the second quarter. Telemetry Investments L.L.C. now owns 90,920 shares of the biotechnology company’s stock worth $440,000 after buying an additional 29,878 shares in the last quarter. 12.47% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:BLPH opened at $2.81 on Friday. Bellerophon Therapeutics has a twelve month low of $2.34 and a twelve month high of $9.19. The firm has a market capitalization of $26.71 million, a PE ratio of -1.24 and a beta of -0.48. The company has a 50-day moving average price of $3.03 and a two-hundred day moving average price of $3.72.
A number of brokerages have weighed in on BLPH. Zacks Investment Research upgraded shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research report on Thursday, November 18th. HC Wainwright reiterated a “buy” rating on shares of Bellerophon Therapeutics in a research report on Tuesday, November 16th.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline include PH-ILD, PH-COPD and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.
Recommended Story: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.